Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
225Ac-PSMA-Trillium in Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT06217822Phase 1Recruiting
- Sponsor
- Bayer
- Start
- Mar 2024
- Primary completion
- Nov 2028
- Modality
- Alpha Emitters, Small Molecules
- Countries
- 10
01
Overview
Phase 1, open-label trial of BAY 3563254 in metastatic castration-resistant prostate cancer (mCRPC) (6 arms), sponsored by Bayer. Primary endpoints: Treatment-Emergent Adverse Events, Severity of Treatment-Emergent Adverse Events and 4 more. Started Mar 2024; status: recruiting.
02
Drugs
BAY 3563254
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06217822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06217822.